89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…
Biotechnology
US, San Francisco [HQ]
Strategy & Leadership
Mergers & Acquisitions Beta
M&As
M&A Deals · Breakdown
89bio, Inc. has no acquisition track records yet.
M&A Deals · History
89bio, Inc. has no acquisition track records yet.